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A systemic or topical treatment of mice with a-difluo-
romethylornithine, and irreversible inhibitor of mam-
D1alian ornithine decarboxylase, produced a rapid deple-
tion of epidermal putrescine and spermidine. When 
m.ethylglyoxal bis(guanylhydrazone), another inhibitor 
of polyamine biosynthesis and a potent antiproliferative 
agent, was subsequently administered the epidermal 
concentration of the latter drug rose distinctly higher 
than without a prior difluoromethyl ornithine treat-
D1ent. The combined use of these 2 antimetabolites 
of polyamines also profoundly depressed epidermal 
DNA synthesis, especially in UV-irradiated skin. A 
"priming" with difluoromethyl ornithine may therefore 
offer a means to enhance the epidermal accumulation of 
otherwise poorly absorbed methylglyoxal bis(guanyl-
hydrazone). 
Even though the accumulation of experimental evidence 
suggesting that the natural polyamines putrescine, spermidine, 
and spermine are closely related to the proliferative activity of 
animal tissues already started in early 60's [for ref. see 1], 
interest in polyamine research among dermatologists is rather 
recent. However, a number of experimental and even clinical 
studies on the possible role of poJyamines in mammalian skin 
have rapidly expanded this area of research over a period of 
the last few years. 
Almost without a single exception, the experimental data 
available indicate that the synthesis and accumulation of 
polyamines is closely correlated with the proliferative activity 
of the skin [2]: the activity of ornithine decarboxylase parallels 
the cyclic replicative activity of mouse hair [3], wound healing 
in rat skin is accompanied by a rapid rise of ornithine decar-
boxylase activity [4] and ultraviolet irradiation, known to in-
duce epidermal hyperplasia, produces a dramatic stimulation 
of polyamine synthesis [5,6]. Furthermore, an induction of 
epidermal ornithine decarboxylase by various skin tumor pro-
moters [7-9] is thought to be an integral part of the 2-stage 
skin carcinogenesis. 
Apart from these purely experimental studies, from which 
only some examples have been mentioned, a number of clinical 
s tudies likewise suggests that an altered metabolism of poly-
amines is associated with proliferative disorders of human skin 
in general and with psoriasis in particular. 
Blood levels of spermidine and spermine are distinctly ele-
vated in psoriatic patients [10], and the concentration of poly-
amines is higher in the involved epidermis than in uninvolved 
or normal epidermis [11,12]. Moreover, clinical improvement of 
treated psoriasis is accompanied by decreased cutaneous con-
centrations [13-15] and by lowered urinary excretion of poly-
amines [13). The activities of the biosynthetic decru-boxylases 
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of polyamines are also proposed to be indicators of the degree 
of malignancy in human cutaneous epitheliomas [16]. 
In addition to the aforementioned descriptive clinical studies, 
a few attempts have been made to treat human psoriasis with 
inhibitors of polyamine synthesis. By using difluoromethyl or-
nithine (DFMO), an irreversible inhibitor of ornithine decar-
boxylase [17], Grosshans et al [12] achieved a significan t reduc-
tion of cutaneous putrescine and spermidine concentrations 
that was associated with a moderate improvement of the disease 
conditions in most patients. Methylglyoxal bis(guanyl-
hydrazone) (MGBG) and a-methylornithine have been re-
ported to depress adenosylmethionine decarboxylase and orni-
thine decarboxylase activities in lesional psoriatic epidermis 
[18). 
We recently found that 2 antimetabolites of polyrunines, 
namely DFMO and MGBG, interact with each other in a 
unique way: putrescine and spermidine depletion produced by 
DFMO, resulted in a strikingly enhanced uptake of MGBG in 
cultmed animal cells [19] and in tumor cells grown in the 
peritoneal cavity of mice [20]. 
In the present communication we have applied this idea of 
sequential treatment with DFMO and MGBG in order to 
achieve higher concentrations of the latter drug in mouse 
epidermis. 
MATERIALS AND METHODS 
Animals 
Female albino mice were used in all experiments. After an init ial 
haircut with scissors, the dorsal hair was removed wi th the aid of cream 
hair remover. Only animals showing no regrowth of hair were used. 
Irradiat ion of the shaved skin was accomphshed with UV-B lamp 
(Amn, 310 nm, Au·am, Finland) for 12 min at a distance of 40 em (total 
radiation dose 0.15 J /cm2) . 
Preparation of Epidermal Samples for Analytical Determinations 
The mice were killed by decapitation. The dorsal skin was washed 
with water, dried, and excised with small scissors. The skin was then 
immersed into a 55°C potassium phosphate buffer (50 mM, pH 7.4) for 
30 seconds whereafter it was cooled in cold buffer. The pieces of skin 
were stretched on a plastic fUm and the epidermal tissue was scraped 
off. The tissue was weighed and homogenized in 0.2 M perchloric acid 
for polyamine, MGBG and DNA .determinations. For enzyme assays, 
the epidermal preparations were disintegrated by homogenation in 25 
mM Tris-HCl buffer, pH 7.4 , containing 0.1 mM EDTA and 1 mM 
dithiothreitol. The homogenates were centrifuged at 100,000 xg fo r 20 
min and resulting supernatant fractions were used for enzyme assays. 
Chemica.ls 
Ditluoromethylornithine was a generous gift from the Centre de 
Recherche Merrell International (Strasbourg, France). The animals 
received the drug in the drinking water (3% solution) and got additional 
intraperitoneal injections (600 mg/kg). For topical administration 
DFMO was mixed with Novalan base (Orion, Espoo, Finland). Meth-
ylglyoxal bis(guanylhydrazone) was purchased from Ega-Chemie 
(Steinheim/ Albuch, Germany). S-Adenosyl-L-[I- '4C]methionine was 
prepared enzymically as in [21]. [3H]Thymidine (specific radioactivity 
30 Cilmol) was obtained from the Radiochemical Centre (Amersham, 
U.K.). 
Analytical M ethods 
The activity of adenosylmethionine decarboxylase was assayed as in 
[22]. Polyamines were determined from perchloric acid ext racts by the 
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meth od of Seiler [23) using the solvent system of Dreyfuss et al [24). 
MGBG was determined enzymically from neutralized perchloric acid 
extracts by the method of Seppiinen et al [25) using adenosylmethionine 
decarboxylase isolated from baker's yeast. DNA was me~sured by the 
method of Giles and Myers [26] and protein by the method of Lowry 
et al [27). The amount of radioactivity incorporated into DNA was 
determined by liquid scintillation counting of the acid-hydrolyzed sam-
ples. 
RESULTS 
Initial experiments indicated that topical MGBG was only 
poorly absorbed percutaneously in normal mouse skin. From 
the vehicles tested, the best rate of absorption was obtained 
when the drug was applied in 85% acetone. 
As shown in Table I, 3 topical applications of MGBG (in 
acetone) at 6-hr intervals resulted in measurable epidermal 
drug concentrations in untreated mice. The fact that at least a 
part of the drug was located intracellularly was supported by 
the fmding revealing that epidermal adenosylmethionine de-
carboxylase activity was strikingly enhanced in response to 
MGBG treatment (Table I) . The latter phenomenon is based 
upon the fact that MGBG (as a competitive inhibitor) stabilizes 
the enzyme resulting in a paradoxic enhancement of its activity ' 
when measured in dialyzed or highly dilute tissue extracts (28]. 
When the mice were fIrst treated with systemically adminis-
tered DFMO (which resulted in a clear putrescine and spermi-
dine depletion) prior to the application ofMGBG, the epidermal 
accumulation of the latter drug was apparently enhanced. Ow-
ing to. the large variations between the experimental animals, 
the dlfference was not statistically signifIcant. The observed 
variations of the individual MGBG concentrations are probably 
related to the difficulties of proper washing off the topically 
TABLE 1. Effect of DFMO treatment on the accumulation of 
toptcally administered MGBG in mouse epidermis 
Adenosylme- MGBG concentration 
Putrescine thionine 
Treatment (nmol/mg decarboxylase Epidermis 
DNA) activity (nmol/mg Blood (nmol/mg pro- (I'M) 
tein/h) DNA) 
None (n - 4) 51 ± 14" 0.31 ± 0.04 
DFMO· (n = 4) 17 ± 4· 0.15 ± 0.01·· 
MGBG' (n = 4) 121 ± 26 9.66 ± 1.71·' IB .2 ± 6.4 0.42 ± 0.04 
DFMO· + MGBG' 62 ± 9 10.60 ± 1.B1·· 40.4 ± 1B.1 0.44 ± 0.12 
(n = 4) 
"Mean ± SEM. 
I, bFMO was. given in drinking water (3%) for 4B hr and injections of 600 mg/ 
kg were gIven In addItIon 3 tImes a day. The amount of DFMO obtained in 
drinldng water totalled to 240 mg/animal/day. Additional injections were given 
at daytIme to balance the drug delivery, since most the drinking water was 
consumed during the nights. 
, 10 mM MGB~ was applied topically in 85% acetone 3 times (every 6 hr, 
contemporarily WIth DFMO InJectIOns). 
• p < 0.05; •• p < 0.01. 
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applied MGBG prior to the actual drug assays. Due to this fact 
the rest of the experiments were peIformed using intraperito~ 
neally administered MGBG. 
When untreated mice were given a single intraperitoneal 
injection of MGBG, epidermal samples again contained easily 
measurable, yet low, drug concentrations (Table II) . A previous 
treatment with DFMO before the injection of MGBG signifI-
cantly enhanced the accumulation of the latter drug in the skin 
but by far the highest epidermal MGBG concentrations wer~ 
obt~ined by exposing DFMO-treated mice to UV-B irradiation 
(whIch latter treatment alone only marginally increased epider-
mal MGBG levels) (Table II). The combination of DFMO and 
MGBG not only effectively prevented the irradiation-induced 
increases in putrescine and spermidine concentrations but also 
abolished the enhancement of epidermal DNA synthesis in 
response to the irradiation (Table II). It is noteworthy that 
although the treatment with DFMO enhanced the epidermal 
accumulation of systemically administered MGBG, the low 
blood concentrations of the drug were virtually unaffected 
(Table II) . 
We next tried whether topically applied DFMO would be 
effective in decreasing epidermal polyamine concentrations 
and whether a possible local polyamine depletion would en~ 
?ance the epidermal accumulation of intraperitoneally admin-
Istered MGBG. Table III shows that topical applications of 
mouse dorsal skin with DFMO indeed resulted in a marked 
decrease in epidermal putrescine and spermidine content in 
comparison with mice treated with the vehicle only. When the 
experiment was repeated and, after the development of epider-
mal pu.tr~sci~e and spermidine .depri.vation, a ~ingle intraperi-
toneal m]ectIOn ofMGBG was gIven, It was ObVIOUS that topical 
treatment with DFMO also strikingly enhanced the accumula-
tion of MGBG in mouse epidermis without affecting the blood 
levels of the drug (Table IV). 
DISCUSSION 
Rapidly accumulating experimental evidence suggests that 
the natural polyamines are closely associated with, or probably 
TABLE III. Epidermal polyamine depletion produced by topically 
administered DFMO 
Treatment 
Vehicle (n = 4) 
DFMO" (n = 4) 
" Mean ± SEM. 
Putrescine 
60 ± 8" 




471 ± 31 
224 + 24·" 
Spermine 
204 ± 7 
358 ± 22'" 
" 20% DFMO (in Novalan base) was applied t.i.d. (300 mg each time) 
on mouse dorsal skin for 2 days . 
,., P < 0.001. 
TABLE II. Effect of DFMO and UV·B irradiation on the accumulation o( sy.stematically administered MGBG, on the concentration of 
polyammes and on DNA synthes~s m mouse eptdermis 
MGBG concentration Polyamine concentration 
Treatment (nmol/mg DNA) 
before MGBG" Epidermis Blood 
(nmol/mg DNA) (pM) PutTescine Spermidine 
None (n 4) 2.9 ± 0.5" 1.3 ± 0.1 107 ± 7 466 ± 12 
DFMOc (n = 4) 6.2 ± 1.4 ' 0.9 ± 0.1·- 16 ± 2'·' 288 ± 18·' 
UV-Bd (n = 5) 3.9 ± 1.2 1.2 ± 0.1 205 ± 9"· 842 ± 28·'-
DFMOc + UV-Bd 36.9 ·± 8.6" 1.8 ± 0.5 19± 2'" 328 ± 31" 
(n = 5) 
" Each animal received an intraperitoneal injection of MGBG (30 mg/ kg) 4 hr before death . 
"Mean ± SEM. 
C DFMO was given as in Table 1 for 96 hr. 
Spermine 
145 ± 10 
198 ± 17 
132 ± 4' 
234 ± 24" 
d The animals ~ere irradiated with UV-B light, Amn, 310 nm 48 hr before death. The total dose was 0 15 J /cm2 
.; [JH]Thymidine (30 !lei/animal) was injected intraperitoneaLly 1 hr before death. . . . 
, P < 0.05; ,. P < 0.01; .,' P < 0.001. 
["H ]Thymidine 
incorporation' 
(cpm/ mg DNA) 
80 ± 9 
53 ± 10 
190±17·-
96 ± 11 
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TABLE IV. Effect of topically applied DFMO on the accumulation of systematically a.dministered MGBG and on polyamine concentra.tions 




Vehicle (n = 4) 
DFMOc (n = 4) 
MGBG concentration 
Epidermis (nmol/mg DNA) 
12.6 ± 1.61> 
51.0 ± 7.6" 
Blood (I'M) 
0.93 ± 0.26 
0.63 ± 0.03 
Putrescine 
70 ± 4 




905 ± 112 
419 ± 54' 
Spermine 
263 ± 16 
358 ± 24* 
" Each animal received an intraperitoneal injection of MGBG (30 mg/kg) 4 hr before death. 
" Mean ± SEM. 
c 20% DFMO (in Novalan base) was applied t.i.d. (300 mg each time) on mouse dorsal epidermis for 4 days. 
* P < 0.05; "P < 0.01; '" P < 0.001. 
required for, cell proliferation in a variety of mammalian sys-
tems. The latter view is not only based on an ever increasing 
descriptive and circumvential evidence, but is also substanti-
ated by the findings indicating that a chemical intervention of 
polyamine biosynthesis with the aid of compounds capable of 
preventing their formation in vivo rapidly leads to an antipro-
liferative effect (for ref. see [29]) . 
The most useful antimetabolites of polyamines currently 
available obviously are DFMO, a specific inhibitor of putrescine 
formation [17] and MGBG, an inhibitor of spermidine and 
spermine synthesis [30]. A sequential administration schedule 
of these 2 drugs leads to an interaction which efficiently inhibits 
cell proliferation. Treatment with DFMO depletes animal cells 
of putrescine and spermidine (but causes a small increase in 
spermine level) leading to a marked decrease of the total 
polyamine content of the cell. The polyamine deprivation trig-
gers a series of compensatory mechanisms by which the cells 
attempt to normalize their intracellular polyamine pools [31]. 
These include the stimulation of the uptake of extracellular 
polyamines [19,20]. By virtue of its structural resemblance to 
spermidine, the uptake of MGBG is similarly enhanced leading 
to high (up to lOmM) intracellular drug concentrations and 
rapid cell death [19,20]. 
As demonstrated in the present communication, this 
"priming" concept with DFMO appears likewise to be applica-
ble to enhanced epidermal accumulation of MGBG. Whether 
the treatment schedule can be used clinically in the treatment 
of proliferative skin disorders like sporiasis remains to be tested. 
The ideal mode of treatment should obviously be topical ad-
ministration of both drugs. The toxicity of high doses ofMGBG 
is well documented, and its systemic administration may be 
justified only in life threatening conditions [32]. Topical admin-
istration to limited lesional areas would most probably elimi-
nate the danger of any systemic side effects. Unlike MGBG, 
DFMO is practically nontoxic; it has been administered at high 
doses to leukemia patients with no apparent side effects [33]. 
Careful dose dependence studies are, however, clearly required 
to define the optimal doses for effective and specific treatment. 
As it appears to us, possibilities for topical treatment are 
hampered by the poor percutaneous absorption of the highly 
polarized MGBG molecule. The high (10 mM) concentration of 
MGBG required for the accumulation of the drug into epider-
mal cells clearly suggests that most of it simply does not 
penetrate through the skin. An improved penetration of MGBG 
could conceivably be achieved by suitable vehicles and/or by 
modification (reversible?) of the chemical entity itself. 
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